Table 1.
Patient Characteristics
| Antibody-Mediated Rejection (AMR) | P- Valuea |
AMR-Free (n=1,799; 89.7%) |
||||
|---|---|---|---|---|---|---|
| Overall (n=207; 10.3%) |
C4d-Negative AMR (n=51; 2.5%) |
C4d-Positive AMR (n=156; 7.8%) |
||||
| Age at Transplant (SD) | 46.1 (13.7) | 47.5 (15.8) | 45.7 (13.0) | 0.4 | 52.1 (14.3) | |
| Deceased Donor Transplant | 54 (26.1%) | 14 (27.4%) | 40 (25.6%) | 0.8 | 965 (53.6%) | |
| Female | 118 (57.0%) | 32 (62.7%) | 86 (55.1%) | 0.3 | 749 (41.6%) | |
| Black Race | 52 (25.1%) | 13 (25.5%) | 39 (25.0%) | 0.9 | 623 (34.6%) | |
| Cause of ESRD | 0.2 | |||||
| Glomerular Diseases | 79 (38.2%) | 14 (27.4%) | 65 (41.7%) | 449 (25.0%) | ||
| Diabetes Mellitus | 18 (8.7%) | 8 (15.7%) | 10 (6.4%) | 348 (19.3%) | ||
| Hypertensive Nephrosclerosis | 41 (19.8%) | 9 (17.6%) | 32 (20.5%) | 547 (30.4%) | ||
| Polycystic Kidney Disease | 20 (9.7%) | 6 (11.8%) | 14 (9.0%) | 167 (9.3%) | ||
| Renovascular & Other Vascular Diseases | 5 (2.4%) | 2 (3.9%) | 3 (1.9%) | 10 (0.6%) | ||
| Other or Missing (includes Tubular and Congenital) | 44 (21.3%) | 12 (23.5%) | 32 (20.5%) | 278 (15.4%) | ||
| Time on Dialysis Prior to Recent Transplant | 0.2 | |||||
| Preemptive | 14 (6.8%) | 2 (3.9%) | 12 (7.7%) | 330 (18.3%) | ||
| ≤2 years | 26 (12.6%) | 4 (7.8%) | 22 (14.1%) | 579 (32.2%) | ||
| 2–6 years | 48 (23.2%) | 17 (33.3%) | 31 (19.9%) | 559 (31.1%) | ||
| ≥6 years | 119 (57.5%) | 28 (54.9%) | 91 (58.3%) | 331 (18.4%) | ||
| Donor Age (SD) | 42.0 (13.1) | 42.3 (13.5) | 41.8 (12.9) | 0.8 | 40.3 (15.0) | |
| Median Follow-Up Time (Years; IQR) | 4.0 (2.0–6.0) | 3.0 (1.0–5.0) | 4.0 (2.0–6.0) | 0.055 | 3.7 (1.0–6.0) | |
AMR - antibody-mediated rejection, SD - standard deviation, ESRD - end stage renal disease, IQR - interquartile range
a
P-value refers to the statistical test comparing C4d-negative AMR patients and C4d-positive AMR patients.